Gale Sebastian

Clinical Assistant Professor

University of Washington
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Year:

2025

Microbiota disruptions have been associated with short-term complications after allogeneic hematopoietic cell transplantation (alloHCT). However, only a few studies have examined the relationship between dysbiosis and chronic graft-versus-host disease (cGVHD), the main long-term immunologic toxicity of alloHCT. Considering the role of oral microbiota in systemic inflammatory diseases, we evaluated whether oral microbiota at day 28 post-HCT corresponding to clinical recovery from the acute events after transplantation is associated with subsequent cGVHD. Shotgun metagenomic sequencing of 207 saliva and supragingival plaque samples collected longitudinally at baseline (pre-conditioning), day +28, and day +84 from 37 patients (11 with subsequent moderate/severe cGVHD) revealed a significant association between day +28 plaque microbiota composition and cGVHD. Two orthogonal statistical approaches demonstrated Streptococcus sanguinis and Prevotella loescheii in day +28 plaque to be associated with cGVHD. Metagenome-based functional analysis identified 4 microbial metabolic pathways associated with future cGVHD, two of which were highly attributed to S. sanguinis. These pathways – ethanolamine utilization and glycerol metabolism – increase bacterial fitness by providing an alternative carbon/nitrogen source and improving survival in inflamed tissues. Our findings propose a novel mechanism by which the early post-transplant dental biofilm may contribute to cGVHD months later, offering a potential target for early prophylactic intervention.

Year:

2025

Oral acute graft‐versus‐host disease (aGVHD) is rare and with no diagnostic criteria. We report a case of oral aGVHD with three clinical phases. A self‐limited prodrome of largely subjective oral symptoms was followed by concurrent oral and upper gastrointestinal aGVHD. Six months after transplantation, the patient was diagnosed with severe oral and upper gastrointestinal chronic GVHD. We compared the salivary microbiota of our patient at the time of diagnosis of aGVHD with 50 contemporaneous transplant recipients and found no evidence for oral microbiota involvement in pathogenesis. This in‐depth N‐of‐1 analysis reveals novel aspects of oral aGVHD pathogenesis.

Year:

2024

Year:

2024

Oral mucositis (OM) is a common early complication of allogeneic hematopoietic cell transplantation (alloHCT), causing pain, infections, swallowing/speech impairment, and prolonged hospitalization. As there are no approved prophylactic or therapeutic approaches for alloHCT-associated OM, management remains supportive and limited largely to narcotic analgesics, ice chips, and total parenteral nutrition. A better understanding of OM pathogenesis may yield novel targets for intervention. We hypothesized that the oral microbiota may mediate OM pathogenesis. We conducted a prospective single-center study including longitudinal mucositis assessment using the Oral Mucositis Assessment Scale (OMAS) and multi-site oral sample collection by calibrated oral medicine specialists. Mucositis assessment was performed at baseline, day +7, day +14, day +21, day +28, and day +84. Total mucositis score (range 0-45) at each timepoint was calculated as the sum of all scores (ulceration and erythema) across all sites and used to classify OM severity (total score ≤ median vs. > median across all examinations). Saliva (baseline and days +14, +28, and +84), supragingival plaque (baseline and days +14, +28, and +84), and subgingival plaque (baseline) samples underwent shotgun metagenomic sequencing, targeting a sequencing depth of 20M read pairs per sample. MetaPhlAn4 was used for species-level taxonomic assignment. MaAsLin2 (Microbiome Multivariable Association with Linear Models) was used to identify microbiota predictors of OM severity at days +7, +14, and +21. Species abundances in different oral sites at the same or the closest preceding OM assessment timepoint for the same patient were included in the model. A significance threshold of 0.05 was considered for P values, or Benjamini-Hochberg q values in case of multiple testing. Fifty-two patients were enrolled (median age 43, M:F ratio 1). Despite the original plan at the time of consent, 9 patients received reduced-intensity conditioning due to newly discovered comorbidities; these patients were included. Mucositis severity increased rapidly until day +7, followed by a slower rise to a peak at day +14. It then rapidly improved until day +21. Further improvement occurred until day +28, followed by complete resolution by day +84 in most patients. Significant clinical predictors of worse OM were male sex for day +7 (P = 0.01), myeloablative conditioning for day +14 (P = 0.01), older age for day +21 (P = 0.01), and diseases other than acute leukemia for day +84 (P = 0.03). Salivary flow rate was not associated with OM (Wilcoxon's P for baseline, day +14, day +28, and day +84 timepoints: 0.47, 0.68, 0.30, and 0.80, respectively). A total of 455 samples were analyzed. The strongest associations were between day +14 OM and baseline salivary microbiota: Prevotella nanceiensis (more severe OM; q = 0.07), an unclassified actinomyces species (sp. ph3) (less severe OM; q = 0.007), and an unclassified schaalia species (SGB17158, less severe OM; q = 0.07). A composite baseline salivary score calculated as Prevotella nanceiensis - (Actinomyces sp. ph3 + Schaalia SGB17158) was significantly higher in patients with more vs. less severe OM at day +14 (P = 2x10-5), with a high prediction accuracy (AUC 85%; 95%CI 75%-96%). This score was not associated with other baseline characteristic such as age (P = 0.69), sex (P = 0.78), disease (P = 0.34), salivary flow rate (P = 0.24), or exposure to antibiotics with ≥10% exposure rate within 2 weeks before the baseline sample (P for TMP-SMX and fluoroquinolones 0.25 and 0.73, respectively). When the same score was calculated at different timepoints, no change was apparent over time, despite post-HCT antibiotic exposures and other microbiota insults. In summary, we have found a predictive biomarker of OM after alloHCT using baseline salivary microbiota. The score identified here is a remarkably stable, intrinsic, subject-level characteristic of the oral microbiota, predis

Year:

2024

Oral mucositis (OM) is a common early complication of allogeneic hematopoietic cell transplantation (alloHCT), causing pain, infections, swallowing/speech impairment, prolonged hospitalization, and poor quality of life. As there are no approved prophylactic or therapeutic approaches for alloHCT-associated OM, management remains supportive and limited largely to narcotic analgesics, ice chips, and total parenteral nutrition. Some, but not all studies have found higher rates of OM after total body irradiation (TBI)- vs. chemotherapy-based myeloablative conditioning. However, methods used for mucositis assessment have been inconsistent and somewhat limited, likely leading to inconsistent results. We hypothesized that comprehensive, longitudinal mucositis assessment performed by calibrated Oral Medicine specialists will address this knowledge gap. In addition, we examined whether a signature of differential effects by the specific conditioning modality is present in supragingival plaque microbiota, a site not previously profiled in alloHCT recipients. We conducted a prospective single-center study including longitudinal mucositis assessment using the Oral Mucositis Assessment Scale (OMAS) and supragingival plaque collection by 4 calibrated Oral Medicine specialists. We classified patients into 2 cohorts: those receiving high-dose TBI (12-13.2 Gy)-based vs. chemotherapy-based myeloablative conditioning. Mucositis assessment was performed at baseline and days +7, +14, +21, +28, and +84. Total mucositis score (range 0-45) at each timepoint was calculated as the sum of all scores (ulceration and erythema) across all sites. Supragingival plaque samples (baseline and days +14, +28, and +84) were profiled using shotgun metagenomic sequencing, targeting a sequencing depth of 20M read pairs per sample. MetaPhlAn4 was used for species-level taxonomic assignment. When the overall microbiota composition in principal coordinates analysis was significantly different between the 2 cohorts at a given timepoint, MaAsLin2 (Microbiome Multivariable Association with Linear Models) was used to identify taxonomic differences. A significance threshold of 0.05 or 0.10 was considered for P values or Benjamini-Hochberg q values (in multiple testing), respectively. A total of 43 patients (23 females) were included: TBI cohort (N = 20; 46%) vs. chemotherapy cohort (N = 23; 54%). Most common TBI- and chemotherapy-based regimens were Cy/TBI and Flu/Bu4 in 16 (80%) and 12 (52%) patients, respectively. The chemotherapy cohort was older (median age 52 vs. 37). Acute leukemia was the most common underlying disease (78% vs. 80% of patients in the chemotherapy vs. TBI groups, respectively). Methotrexate was used as a component of GVHD prophylaxis in 70% and 75% of patients in chemotherapy and TBI cohorts, respectively. OM severity peaked at day +7 in the TBI cohort vs. day +14 in the chemotherapy cohort. Afterwards, OM improved in both cohorts and remained similar until day +84. Day +14 OM was more severe in the chemotherapy cohort compared to the TBI cohort (P = 0.004). The comparison at other timepoints was not significant. Other clinical predictors of worse OM were male sex for day +7 (P = 0.008) and older age for day +21 (P = 0.03) mucositis. There was no difference in supragingival microbiota diversity between the 2 cohorts at any of the timepoints. While baseline microbiota composition was similar between the 2 cohorts, a noticeable difference was present at days +14 (P = 0.04), +28 (P= 0.005), and even +84 (P = 0.07). Differential abundance analysis revealed enrichment of Prevotella melaninogenica and Scardovia wiggsiae in the TBI cohort and a Rothia species in the chemotherapy cohort. In a collaborative multi-aspect longitudinal study between alloHCT and Oral Medicine teams, we demonstrated different dynamics and severity of OM after myeloablative alloHCT depending on whether conditioning was TBI- vs. chemotherapy-based. In addition, in this first profiling

Year:

2024

Collaborators (3)

Armin Rashidi

Associate Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Hakan Gem

Attending Faculty

Fred Hutch Cancer Center

UNITED STATES
View details

David Dean

Clinical Associate Professor

University of Washington

UNITED STATES
View details